This major expansion will enable Catalent to offer formulation development and optimization services in its Winchester, Kentucky facility andcomplements that site's existing pilot scale and commercial capabilities for controlled release tablets and capsules. The addition of formulation development and optimization services in Winchester will allow products to move through the development stages to commercialization within the same site; reducing the need for additional technology transfers and facilitating a faster time to market. This expansion also builds upon Catalent's existing controlled release development capabilities in Somerset, New Jersey andSchorndorf, Germany.
“This latest investment in our modified release group continues our long established heritage in this field and offers our customers a more comprehensive service at our Winchester facility and across our network,” said Ian Muir, President of Catalent's Modified Release Technology business.
This new formulation and process development area is expected to be open for business in early December and is representative of Catalent's commitment to growth and is in line with customer needs. Maintaining this momentum, a major expansion of development and commercial capabilities in Catalent's Schorndorf, Germany oral controlled release facility is underway for a planned launch in 2012 and will allow global and European customers to take advantage of Catalent's extensive expertise in solving the most complex formulation and scale-up challenges.
For more information or to schedule a follow-on interview, please contact Patricia McGee atmedia@catalent.com or stop by the Catalent booth (#1901) at the upcoming AAPS Annual Meeting in New Orleans.
“This latest investment in our modified release group continues our long established heritage in this field and offers our customers a more comprehensive service at our Winchester facility and across our network,” said Ian Muir, President of Catalent's Modified Release Technology business.
This new formulation and process development area is expected to be open for business in early December and is representative of Catalent's commitment to growth and is in line with customer needs. Maintaining this momentum, a major expansion of development and commercial capabilities in Catalent's Schorndorf, Germany oral controlled release facility is underway for a planned launch in 2012 and will allow global and European customers to take advantage of Catalent's extensive expertise in solving the most complex formulation and scale-up challenges.
For more information or to schedule a follow-on interview, please contact Patricia McGee atmedia@catalent.com or stop by the Catalent booth (#1901) at the upcoming AAPS Annual Meeting in New Orleans.
Companies in this article
